Impact of HLA Polymorphism on the Immune Response to Bacillus Anthracis Protective Antigen in Vaccination versus Natural Infection.
Author
Ascough, StephanieIngram, Rebecca J
Chu, Karen K Y
Moore, Stephen J
Gallagher, Theresa
Dyson, Hugh
Doganay, Mehmet
Metan, Gökhan
Ozkul, Yusuf
Baillie, Les
Williamson, E Diane
Robinson, John H
Maillere, Bernard
Boyton, Rosemary J
Altmann, Daniel M
Date
2022-09-20Journal
VaccinesType
Article
Metadata
Show full item recordAbstract
The causative agent of anthrax, Bacillus anthracis, evades the host immune response and establishes infection through the production of binary exotoxins composed of Protective Antigen (PA) and one of two subunits, lethal factor (LF) or edema factor (EF). The majority of vaccination strategies have focused upon the antibody response to the PA subunit. We have used a panel of humanised HLA class II transgenic mouse strains to define HLA-DR-restricted and HLA-DQ-restricted CD4+ T cell responses to the immunodominant epitopes of PA. This was correlated with the binding affinities of epitopes to HLA class II molecules, as well as the responses of two human cohorts: individuals vaccinated with the Anthrax Vaccine Precipitated (AVP) vaccine (which contains PA and trace amounts of LF), and patients recovering from cutaneous anthrax infections. The infected and vaccinated cohorts expressing different HLA types were found to make CD4+ T cell responses to multiple and diverse epitopes of PA. The effects of HLA polymorphism were explored using transgenic mouse lines, which demonstrated differential susceptibility, indicating that HLA-DR1 and HLA-DQ8 alleles conferred protective immunity relative to HLA-DR15, HLA-DR4 and HLA-DQ6. The HLA transgenics enabled a reductionist approach, allowing us to better define CD4+ T cell epitopes. Appreciating the effects of HLA polymorphism on the variability of responses to natural infection and vaccination is vital in planning protective strategies against anthrax.Identifier to cite or link to this item
http://hdl.handle.net/10713/20100ae974a485f413a2113503eed53cd6c53
10.3390/vaccines10101571
Scopus Count
Collections
Related articles
- Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunity.
- Authors: Ascough S, Ingram RJ, Chu KK, Reynolds CJ, Musson JA, Doganay M, Metan G, Ozkul Y, Baillie L, Sriskandan S, Moore SJ, Gallagher TB, Dyson H, Williamson ED, Robinson JH, Maillere B, Boyton RJ, Altmann DM
- Issue date: 2014 May
- CD4+ T Cells Targeting Dominant and Cryptic Epitopes from Bacillus anthracis Lethal Factor.
- Authors: Ascough S, Ingram RJ, Chu KK, Musson JA, Moore SJ, Gallagher T, Baillie L, Williamson ED, Robinson JH, Maillere B, Boyton RJ, Altmann DM
- Issue date: 2015
- Development of a novel multiepitope chimeric vaccine against anthrax.
- Authors: Aggarwal S, Somani VK, Gupta S, Garg R, Bhatnagar R
- Issue date: 2019 Apr
- Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes.
- Authors: Ingram RJ, Metan G, Maillere B, Doganay M, Ozkul Y, Kim LU, Baillie L, Dyson H, Williamson ED, Chu KK, Ascough S, Moore S, Huwar TB, Robinson JH, Sriskandan S, Altmann DM
- Issue date: 2010 Apr 1
- Characterization of the UK anthrax vaccine and human immunogenicity.
- Authors: Modi T, Gervais D, Smith S, Miller J, Subramaniam S, Thalassinos K, Shepherd A
- Issue date: 2021 Mar 4